Ma's Bamboo-Based Medicinal Moxibustion Therapy of Low Back Pain in Lumbar Disc Herniation: Study Protocol for a Randomized Controlled Trial

Xian-Zhu Wang

Guizhou University Of Traditional Chinese Medicine

Jin Cui (✉ 516260179@qq.com)

Guizhou University Of Traditional Chinese Medicine <https://orcid.org/0000-0002-0106-2620>

Jing FU

Guizhou University Of Traditional Chinese Medicine

Kai-Yang Xue

Guizhou University Of Traditional Chinese Medicine

Ping-Nan Chen

Guizhou University Of Traditional Chinese Medicine

Cai-Hong Xiao

Guizhou University Of Traditional Chinese Medicine

Research Article

Keywords: LDH, Low back pain, Ma's bamboo-based medicinal moxibustion therapy, Acupuncture, Randomized controlled trial

Posted Date: January 12th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-850406/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Lumbar disc herniation (LDH) is a common and frequently-occurring disease in clinic. Low back pain and sciatica are the presenting symptoms of LDH. To some extent, it can be considered that measures with the capability to improve low back pain or sciatica have the potential to treat LDH. Ma's bamboo-based medicinal moxibustion therapy can effectively reduce the degree of low back pain and has been widely used. Studies of small sample size have seen significant improvement on pain relief.

Methods/design:

The trial is a multicenter, randomized, parallel-group, non-inferiority study. Three hundred and twelve patients will be randomly assigned to a Ma's bamboo-based medicinal moxibustion group (n=156) and an acupuncture group (n=156). Patients in each group will receive treatment every day, 6 times a week, 12 times in total. Follow-up will be conducted 14 days after treatment. The primary outcome will be the visual analogue scale (VAS) at baseline, after 6 times of treatment, the end of treatment, and follow-up. The secondary outcomes will include Oswestry disability indexes (ODI), modified Japanese Orthopaedic Association low back pain (M-JOA) score, serum β -endorphin (β -EP) and serum substance P (SP). β -EP and SP as well as safety evaluation indexes (routine blood test, liver and kidney function, and ECG) will be measured at baseline and after the end of treatment.

Discussion

The results of the trial will compare the efficacy on low back pain in LDH between Ma's bamboo-based medicinal moxibustion group and acupuncture group and will be expected to make a systematic and objective evaluation on the clinical efficacy and safety of Ma's bamboo-based medicinal moxibustion therapy.

Trial registration:

ChiCTR, ChiCTR2000038725. Registered on 29 September 2020.

Background

Lumbar disc herniation (LDH) is a syndrome caused by the compression and stimulation of lumbosacral nerve root and cauda equina nerve owing to the degeneration of lumbar intervertebral disc, rupture of annulus fibrosus and resulted nucleus pulposus protrusion. It occurs frequently in young and middle-aged individuals, with a higher incidence in males than females, among which L4/5 and L5/S1 are the vulnerable sites (>90%)^[1]. Low back pain is the initial symptom of LDH, which is generally in the

lumbosacral part, mostly soreness and swelling pain, which can radiate to the buttocks. It occurs repeatedly, aggravates after sitting, standing for a long time or fatigue, and relieves after rest^[2]. Clinically, low back pain may be induced by multiple factors. However, among patients with low back pain, outpatients and inpatients with LDH account for 10% ~ 15% and 25% ~ 40%, respectively^[3]. there is a high incidence of LDH but low rate of hospitalization. Most patients with LDH can be relieved after formal conservative treatment^[4].

Low back pain and sciatica are the presenting symptoms of LDH. To some extent, it can be considered that measures with the capability to improve low back pain or sciatica have the potential to treat LDH^[1]. In relative to the oral and surgical treatment of low back pain in LDH, acupuncture exhibits possible advantages in avoiding possible gastrointestinal adverse reactions of oral drugs and the secondary trauma of surgery. Meanwhile, existing systematic reviews^[5, 6], Meta analysis^[7] and randomized controlled studies^[8, 9] support that acupuncture has a good analgesic effect on low back pain. The Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians^[10] and the Chinese Expert Consensus on "Rehabilitation Treatment of Lumbar Disc Herniation" issued by the Skeletal Muscle Professional Committee of the Rehabilitation Physician Branch of the Chinese Medical Doctor Association^[11] all recommend acupuncture as a therapeutic measure for low back pain. Therefore, acupuncture was selected as the control in this study.

Ma's bamboo-based medicinal moxibustion therapy is a characteristic folk diagnosis and treatment technology in china, belonging to the category of herb-partitioned-moxibustion. It has been applied for over 100 years and has accumulated rich clinical experience. Among them, it exhibits the most significant effect on treating low back pain in LDH, cold due to body-deficiency and conditioning of chronic fatigue syndrome.

In our previous research, 14 LDH patients with low back pain were treated with Ma's bamboo-based medicinal moxibustion. The clinical pre-trial found that 2 cases were clinically cured, 4 cases were markedly effective and 6 cases were improved. Besides, the post-treatment VAS score, ODI score and M-JOA score were significantly lower than those before treatment ($P < 0.05$). It suggests that this therapy has certain application value clinically, which, however, lacks evidence-based evaluation. There is an absence of high-level clinical efficacy data, which restricts the real participation of the therapy in clinical decision-making, and hence hinders its clinical popularization and application to a great extent.

Thus, we designed this multicenter randomized controlled trial to assess the efficacy of Ma's bamboo-based medicinal moxibustion therapy on low back pain in LDH, in the hope of obtaining replicable evidences that could rank high on the clinical evidence hierarchy, providing a whole new suitable technology for doctors and patients in clinical.

Methods/design

Study design and setting

This is a parallel, non-inferiority, randomized controlled clinical trial aiming to compare the effect of Ma's bamboo-based medicinal moxibustion therapy and regular acupuncture therapy on low back pain in LDH patients. The patients will be enrolled among outpatients and inpatients from the acupuncture departments of No.1 Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, No.2 Affiliated Hospital of Guizhou University of Traditional Chinese medicine. Eligible patients will be randomly assigned to a Ma's bamboo-based medicinal moxibustion therapy group and an acupuncture group in a 1:1 ratio. All items from the World Health Organization Trial Registration Data Set are shown in Table 1. The study flowchart is provided in Figure 1. A Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist and figure are provided respectively in Additional file 1 and Figure 2.

The protocol has been approved by the ethical committee of No. 1 Affiliated Hospital of Guizhou University of traditional Chinese Medicine (ethical approval number: k2020-039), and the study is registered at Chinese Clinical Trial Registry, ChiCTR (Registration number: ChiCTR2000038725; registration date: September 29, 2020).

Study population

Diagnostic criteria

The diagnostic criteria ^[2]are:

1. Lower limb radiative pain, of which the pain location was consistent with the corresponding affected innervation area
2. Lower limb sensory abnormalities, with decreased superficial sensation of the skin in corresponding affected innervated area
3. Positive result of Lasegue test, Bragard test, Lasegue test of the unaffected side, or femoral nerve stretching test
4. Weaker tendon reflex than that of the unaffected side
5. Muscle weakness
6. Intervertebral disc herniation indicated by lumbar MRI or CT, of which the nerve compression was consistent with the symptoms, signs of the affected nerves
7. In the first five criteria, patients could be diagnosed as LDH when meeting three of them combined with Item 6

Pathological classification^[11]

1. Intervertebral disc bulging, with outward bulge of the annulus fibrosus of the whole intervertebral disc uniformly

2. Localized herniation of the intervertebral disc, rupture of inner layer of annulus fibrosus of intervertebral disc, and partial herniation of nucleus pulposus
3. Intervertebral disc herniation, rupture of most annulus fibrosus of the intervertebral disc, with intact outer annulus fibrosus merely, and the nucleus pulposus confined to the intervertebral disc
4. Prolapse of the intervertebral disc, rupture of all annulus fibrosus of the intervertebral disc, nucleus pulposus tissue protruding out of the intervertebral disc and bound by the posterior longitudinal ligament
5. Sequestered disc herniation, nucleus pulposus tissue protruding out of the annulus fibrosus and posterior longitudinal ligament, and sequestered in the spinal canal

Note: In this trial, patients with pathological classification of intervertebral disc bulging, localized herniation of the intervertebral disc and intervertebral disc herniation will be selected for experiment according to the long-term treatment experience and practice by using Ma's bamboo-based medicinal moxibustion therapy.

Syndrome classification^[12]

1. Low back pain due to cold-dampness evil

The presence of a history of suffering from cold in the waist, aggravation of symptoms when the weather changes or when there is cloudy, rainy or cold weather, with severe cold and pain in the waist, accompanied by numbness or contracture that restricts the body movements of bending or raising up, even with pain involving the lower limbs

2. Low back pain due to dampness-heat evil

Severe and heat pain in the waist, aggravation of symptoms in summer-heat and damp, cloudy and rainy weather, and possible alleviation after activities, accompanied by heavy body and feeling of sleepy, short voiding of reddish urine, yellow and greasy fur on the tongue, as well as soft and frequent pulse or wire and frequent pulse

3. Low back pain due to static blood

The presence of a history of strain or old injury in the waist, aggravation of symptoms when getting up in the morning, tired and sitting for a long while., with stiffness of the muscles on both sides of the waist, pain like the stabbing of a needle, and pain in a fixed site

4. Low back pain due to kidney deficiency

Major manifestations of soreness and weakness, with dull pain, alleviation when pressing and lifting, accompanied by weakness in legs and knees with relief when lying down and repeated onset, with fatigue and hypersomnia, and thready pulse as well

Note: In our study, patients with all the types based on syndrome classification mentioned above will be included for experiment according to the long-term treatment experience and practice by using Ma's bamboo-based medicinal moxibustion therapy.

Inclusion criteria

Patients who meet all of the following criteria were enrolled in the trial:

1. Patients who meet the above diagnostic criteria and pathological classification, with the lesion located in L3-S1
2. Patients aged 18-65 years, males or females
3. Patients with the course of disease ≥ 6 months
4. Drug users with drug withdrawal for 4 weeks, and non-drug users with discontinued treatment for 2 weeks
5. Patients with $3 \leq \text{VAS scores} \leq 6$
6. Willingness to sign written informed consent

Exclusion criteria

Patients who meet any of the following criteria were excluded from the trial:

1. Patients with acute onset of low back pain in lumbar disc herniation
2. Patients with low back pain caused by other causes
3. Patients with other diseases requiring combined treatment using anti-inflammatory and analgesic drugs
4. Patients during pregnancy, lactation or pregnancy preparation
5. Patients with rash, skin damage, ulcers or other infectious diseases at the waist
6. Patients with serious diseases of the heart, liver, kidney, blood system, etc.
7. Patients with mental disorders or communication disorders who could not cooperate
8. Patients with high fever and Yin deficiency

Sample size

The trial is design to determine the efficacy of Ma's bamboo-based medicinal moxibustion therapy on low back pain in LDH and prove that its clinical efficacy is not inferior to normal acupuncture therapy.

Therefore, we chose a non-inferiority trial design. According to the previous literature^[8, 13] and the joint consideration of clinicians and statisticians, it is assume that the standard deviation of VAS score reduction of patients using bamboo-based medicinal moxibustion is 2.0, the non-inferiority limit value is equal to 0.78, with a power ($1-\beta$) of 0.9 ($\alpha = 0.025$, one-sided), and the number of subjects is equal in the two groups. By using PASS(Power Analysis and Sample Size)15 software, the sample size (N) of the

experimental group and the control group are 140 cases respectively. According to the 10% drop-out rate, each group needs at least 156 patients, 312 patients will be recruited in the trial.

Randomization and blinding

There are two investigators at each center (referred to as A and B). Investigator A is responsible for entering baseline data of patients and perform randomization, but he will not know the grouping details and will not participate in the treatment. Investigator B is responsible for performing treatment according to the grouping. At each visit, A is responsible for collecting data and entering the data in the electronic data capture (EDC) system. The therapist and the data collector are separate. Statisticians are responsible for data processing and are not aware of the grouping until the end of the trial. Stratified block randomization will be carried out by third party statisticians who will be not involved in any other part of the trial. Central randomization will be conducted by INTELLIGENCE FUTURE Soft Co., Ltd.(Tianjin, China). A random sequence will be generated with SAS 9.2 (SAS Institute, Inc., Cary, NC, USA) by an independent statistician who is not involved in the study, and the sequence will be stored in a central randomization system (interactive web response (IWR) system). The patients will be stratified based on the two different centers and randomly assigned to the Ma's bamboo-based medicinal moxibustion group and the acupuncture group in a 1:1 ratio. The Ma's bamboo-based medicinal moxibustion group will receive Ma's bamboo-based medicinal moxibustion therapy. Regular acupuncture therapy will be performed on the acupuncture group.

In this trial, patients and therapists will not be blinded due to the uniqueness of the two therapies. Investigators and statisticians will be blinded. Treatment, data collection and data analysis will be conducted by trained practitioners, data collectors and statisticians, respectively, all blinded to one another in order to ensure the reliability of the results.

The conditions for unblinding are: 1) infection or other adverse events, and these patients will be withdrawn from the trial; or 2) the end of the trial and data analysis.

Interventions

All treatments will conduct in the outpatient treatment rooms of the two centers. The therapists will be not involve in the other parts of the trial. The treatments will be performed every day, for a total of 12 treatments. All the treatments will be completed with in 13 days. The assessments of the treatments will be performed after treatment, on the 7th day, the 14nd day, and the 28th day. All practitioners involved in the trial are trained and registered professionals. Acupuncture was performed by primary physicians with >5 years of experience at each center. A training program to standardize all manipulations and filling of a case report form (CRF) will be provided before the trial. Investigators will inform all patients about the possible inconveniences from the trial.

Ma's bamboo-based medicinal moxibustion group

Prior to the treatment, the components of this traditional Chinese medicine prescription will be ground into fine powder, following by mixing and sealing for further use, which include Wei Ling Xian (*Clematidis Radix Et Rhizoma*), Du Huo (*Angelicae Pubescentis Radix*), Rou Gui (*Cinnamomi Cortex*), Xi Xin (*Asari Radix Et Rhizoma*), Chuan Xiong (*Chuanxiong Rhizoma*), Sang Ji Sheng (*Taxilli Herba*), Gui Zhi (*Cinnamomi Ramulus*), etc. (250g each). Components such as Wei Ling Xian (*Clematidis Radix Et Rhizoma*), Ji Xue Ten (*Spatholobi Caulis*), Chuan Niu Xi (*Cyathulae Radix*), Xi Xin (*Asari Radix Et Rhizoma*), Du Huo (*Angelicae Pubescentis Radix*), Chuan Xiong (*Chuanxiong Rhizoma*), Sang Ji Sheng (*Taxilli Herba*) and Rou Gui (*Cinnamomi Cortex*) (200g each) will be placed in 21000mL Liquor and Spirits of 50° for 7 days for subsequent use. Bamboo tube with an inner diameter of 4.5-5.5cm is taken with the stem nodes removed, and cut with a hacksaw according to the specification of 4.5-5.5*4cm (inner diameter * height). Then, with the removal of the bamboo bark on the surface, the edge of the bamboo tube is polished smooth and round to prepare a unique medicinal moxibustion tool. After that, 15g of medicinal powder and 20ml of medicinal wine are mixed evenly, and the finished product is then placed into the medicinal moxibustion tool to press into medicinal cake. In the next step, 3g moxa (Suzhou Medical Appliance Factory, Suzhou, Jiangsu, China) are made into [several](#) moxa-cone with moderate hardness (2.5 cm in height and 2 cm in diameter), which are then place on the compressed powder and ignite for preheating. The moxa-cone are replaced when the medicinal cake will be warm. The patients are informed to take the prone position with the moxibustion sites exposed. L1-L5 Jia ji (EX-B2), Shenshu (BL23), Mingmen Point (GV4) and Yaoyangguan (GV3) are selected for moxibustion. The acupoint positioning is perform in accordance with Nomenclature and location of acupuncture points (GB/T 12346-2006)^[14]. The therapist should ensure that the moxibustion site of the patient is continuously warm without burning pain. The moxa-cone are replaced after burning out, with a total of 3 cones, and the treatment is last for about 40min.

Acupuncture group

The acupuncture group will be treated with 0.30×40 mm, and 0.30×50 mm disposable sterilized filiform needles (Suzhou Medical Appliance Co., Ltd., Suzhou, Jiangsu, China) applied to the Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), L1-L5 Jiaji (EX-B2), and Ashi points. The acupoint selection is formulated according to the major acupuncture point prescription in *the Evidence-Based Guidelines of Clinical Practice with Acupuncture and Moxibustion Low Back Pain*^[15]. Practitioners will perform the treatment according to the national standard of acupuncture manipulation^[16, 17]. The needles will be inserted and manually manipulated until de qi is achieved.

Combined use of drugs

During the whole period of observation, it is suggested that the patients do not use drugs or other methods for the treatment of low back pain in LDH in addition to the experimental scheme. During the treatment period, if the patients take medication by themselves or use other methods of treatment due to aggravated symptoms and unbearable lumbar pain, they will be withdrawn from the trial. The clinicians

will make the appropriate treatments according to the specific conditions of the patient until the symptoms are improved.

Outcome measures

Primary outcome measures

We will use the visual analogue scale as the primary outcome measure^[18]. VAS is one of the sensitive and reliable methods for pain measurement. VAS scores ranged from 0 point to 10 points, which were described in details as follows: 0: painless; Less than 3 points: slight pain that can be tolerable; 4-6 points: pain to affect the sleep, which can be tolerated; 7-10 points: gradually intense pain, which is unbearable and affects appetite and sleep.

Secondary outcome measures

Serum β -endorphin and serum substance P will be used to assess **improvement** of pain in LDH. Previous clinical studies^[19, 20] have reported that the reduction of pain in LDH might be correlated with the levels of serum β -EP and SP, which may be considered as one of the analgesic mechanisms of reducing low back pain in LDH. Methods of detection: At baseline and after the end of treatment, 4ml venous blood samples were collected from patients on an empty stomach in both groups, which were placed in serum separation tubes. Blood samples were then centrifuged at 1000×g for 20 min, the supernatant was then collected and stored in refrigerator at -20°C or -80°C for further measurement. Enzyme-linked immunosorbent assay (ELISA) was used for determination, and the operation was carried out in strict accordance with the instructions of the kit. The test is conducted by the Central Laboratory of No.1 Affiliated Hospital of Guizhou University of Traditional Chinese Medicine.

Oswestry disability index (ODI)^[21, 22] is one of the most widely used scoring scales for functional outcome evaluation of patients with low back pain. It consists of 10 questions, including pain intensity, self-care, lifting, walking, sitting, standing, interference with sleep, sexual life, social life and tourism. A higher score may indicate a more serious dysfunction.

Modified Japanese Orthopaedic Association low back pain (M-JOA) score^[23] is a frequently used scale. It includes subjective symptoms (lumbar pain, lower limb radiative pain and numbness), objective symptoms (paravertebral tenderness, muscle tension, Lasegue test and femoral nerve stretching test) and daily behavior ability (working ability, sleep, bending and lifting). The score ranges from 0 point to 30 points, and a lower score may reveal a milder condition.

Adherence

Before the start of the trial, the investigators will fully inform the patients of the benefits and the possible inconvenience of the study. The patients will sign the informed consent form and volunteer to participate in the study. MRI of the lumbar vertebrae, laboratory examination, and twelve times of treatment will be free of charge in order to improve the adherence of the patients. The baseline data of each patient

(name,gender, age, address, telephone or contacts of immediate family members) will be recorded in detail, hereby to facilitate the supervision of patients' adherence. The cases of drop-out, withdrawal, and discontinuation will be recorded and followed up by telephone or even followed up at patients' homes if necessary.

Data monitoring and management

Our study group will set up a special data monitoring committee for data management and quality control, which consists of hospitals, company, and institute.

Quality control system

All three-level quality monitoring system was established. Clinical research associates (CRAs) were assigned for data monitoring. Level 1 monitoring requires the CRAs in the two hospitals (No. 1 Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, No. 2 Affiliated Hospital of Guizhou University of Traditional Chinese medicine) to monitor the quality of the CRFs once a week, fill out the monitoring report, and report to the principal investigator (PI) in time. Level 2 monitoring requires the CRA from INTELLIGENCE FUTURE Soft Co., Ltd to conduct quality monitoring once every six months, fill out the monitoring report, and report to the project leader of INTELLIGENCE FUTURE in time. Level 3 monitoring requires the person in charge or the technical backbone at the institute of Chinese Medical History and Literature, China Academy of Chinese Medical Sciences to monitor once or twice annually.

Data management platform

The data management platform was set up by INTELLIGENCE FUTURE soft Co., Ltd. It includes the IWR and EDC systems. It includes nine modules, including data entry and statistics. All data will be entered using a double-entry procedure performed by two different individuals.

Statistical analysis

Data analysis will be conducted in accordance with the intention-to-treat principle. Missing data will be handled using linear mixed effects models. Statisticians and chief investigators will work out an analysis plan and related forms before database lock. The analysis will include case distribution, comparison of basic values, compliance, effectiveness, factors that influence efficacy, and safety. Subgroup analysis will be performed to according to pathological classification and syndrome classification. statistical analysis will be conducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). The Wilcoxon rank sum test, t test, or variance analysis will be performed for inter-group or intra-group comparison according to data distribution. The Wilcoxon rank sum test will be used to compare ranked data. The chi-square test will be applied to compare enumeration data. All tests will be one-sided. A p value <0.05 will be considered statistically significant.

Safety monitoring

Possible adverse events during Ma's bamboo-based medicinal moxibustion treatment include itching, scald, redness, blister and infection. Fainting, sticking of needle, hematoma, subcutaneous hematoma, and bleeding might occur during acupuncture treatment. Therapists and subjects are informed to actively report any adverse events during the study. Researchers will track the results of safety evaluation indexes (routine blood test, liver and kidney function, ECG) before and after treatment in a timely manner, and confirm the occurrence of adverse events. Any adverse events that occurs during the trial will be recorded in a CRF by researchers and patients will be treated as soon as possible. Patients may choose to withdraw from the trial due to any adverse events. The sponsor and the data management company INTELLIGENCE FUTURE will monitor the implementation of the trial protocol and filling of CRFs.

Discussion

Ma's bamboo-based medicinal moxibustion therapy is a broad-spectrum folk therapy in china. On the basis of a modification of traditional herb-partitioned-moxibustion, it applies a unique moxibustion method and the ancestral formula for treatment, which shows effect on treating chronic stubborn diseases such as LDH, chronic fatigue syndrome, cold due to body-deficiency and other chronic stubborn diseases. In general, herb-partitioned-moxibustion can play a better role than routine moxibustion by using traditional Chinese medicinal formulae according to different individuals and diseases, which is thus widely used in clinical. It has been demonstrated that herbs-partitioned-moxibustion can alleviate low back pain in LDH^[24, 25]. However, herb-partitioned-moxibustion still has some disadvantages, such as small moxibustion area, weak warm stimulation of moxibustion, weak permeability, easy to fall off to cause scald when burning the moxa-cone, etc. Compared with herb-partitioned-moxibustion, Ma's bamboo-based medicinal moxibustion therapy exhibits advantages in the use of ancestral formula for treatment and the addition of bamboo tube as medicine moxibustion tool. Following the principle of treatment with syndrome differentiation and by using ancestral formula, Ma's bamboo-based medicinal moxibustion has a strong pertinence and can improve the curative effect. Besides, bamboo tube is featured by compact texture and good adsorption, which can increase the coverage area of moxibustion, facilitate the control of the dose of drugs and moxa, is simple and safe to operate and reduce the risk of scald.

The synergistic effect of drugs, moxibustion and acupoints constitutes the therapeutic mechanism of Ma's bamboo-based medicinal moxibustion therapy. The pathogenesis of LDH shows association with the degenerative changes of intervertebral disc, strain, trauma, pregnancy, etc. Low back pain is the primary clinical manifestation of LDH. In traditional Chinese medicine, the pathogenesis of the disease lies in wind-cold-dampness invasion, blood stasis and kidney deficiency. It is the obstruction that causes the pain. Accordingly, the treatment should emphasize on promoting blood circulation, and dredging Qi and blood circulation. In terms of Ma's bamboo-based medicinal moxibustion therapy for the treatment of low back pain in LDH, the traditional Chinese medicine prescriptions consist of Chinese herbal medicine in the folk selected by Ma's family of traditional Chinese medicine in previous dynasties, which are used for external application and rubbing after processing, as well as the medication formula based on their

medical practice experience for many years. According to the pathogenesis characteristics of "wind, cold, blood stasis and deficiency" of low back pain in LDH, the drug formula emphasizes on the use of drugs such as Wei Ling Xian (*Clematidis Radix Et Rhizoma*), Du Huo (*Angelicae Pubescentis Radix*), Sang Ji Sheng (*Taxilli Herba*), Xi Xin (*Asari Radix Et Rhizoma*), Rou Gui (*Cinnamomi Cortex*). It is expected to exert the effects of dispelling wind and relieving pain, warming the interior and dispelling cold, activating blood circulation and removing blood stasis, and tonifying the liver and kidney. For the preparation of medicinal cake, different blending agents are selected according to different diseases in Ma's bamboo-based medicinal moxibustion. For the treatment of low back pain in LDH, powder blending is performed with the application of the medicinal wine made of Ma's traditional Chinese medicine prescription, which is useful for dispelling wind and removing dampness, promoting blood circulation and relieving pain. It can hence stimulate skin tissue, expand capillaries, accelerate drug absorption and improve local blood circulation. Furthermore, on the basis of heat radiation to penetrate skin tissue through heat energy, moxibustion can play the role of anti-inflammation, analgesia, immune regulation and blood circulation improvement^[26]. By the burning of Ma's bamboo-based medicinal moxibustion, the produced warm stimulation, infrared thermal radiation, medicinal chemical factors and physical factors can exert a therapeutic role through regulating the function of human body. Meanwhile, the cuticle of skin at the selected acupoints is significantly thinner than that of the non-acupoints, which is characterized by reduced transdermal barrier effect and good skin permeability. It may be conducive to the percutaneous penetration and absorption of Ma's medicinal cake. In addition, after the application of the Ma's medicinal cake at the acupoint, a closed state in which sweat is difficult to evaporate and diffuse is formed locally. It can increase the moisture content of the cuticle, which may expand into a porous state after hydration to facilitate drug penetration^[27].

Ma's bamboo-based medicinal moxibustion therapy is a characteristic external therapy of traditional Chinese medicine in the folk. It possesses many advantages, such as a wide range of suitable diseases, and small requirements for the operating environment. Moreover, it can be applied by hospitals, families and individuals without special care. It can be used by the patients themselves after explanation and demonstrations by doctors, without relying on doctors with professional technology, which is easy to learn and popularize. Meanwhile, it can exert the curative effect through transdermal absorption of drugs directly on acupoints, avoiding the first-pass effect of oral drugs through the liver and possible gastrointestinal adverse reactions. It may be suitable for long-term continuous treatment of chronic diseases, which can contribute to alleviating the problems of "difficulty and high cost of getting medical service" in ethnic areas. It may be conducive to improve the service capacity of folk medicine and promote the healthy development of ethnic medicine. Besides, it may benefit the improvement of health care level of the people and health service ability in grassroots.

The trial has certain limitations. This protocol is an observational study of clinical efficacy, and most of the efficacy evaluation indexes are recorded by subjective scale. Besides, there is a lack of research based on imaging despite the detection of changes in laboratory indexes. In our subsequent research, we will continue to optimize the study design, take into consideration of more objective indicators to conduct a

more comprehensive study on the mechanism of the proposed therapy in LDH to further verify the curative effect.

Trial Status

The trial is currently recruiting patients and expected to end in December 2021. The first patient was enrolled in November 2020.

Abbreviations

LDH:Lumbar disk herniation; VAS:visual analogue scale; S-EP:β-endorphin; SP:Substance P; ODI:Oswestry disability index; M-JOA; modified Japanese Orthopaedic Association low back pain Score; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; EDC: electronic data capture; IWR: interactive web response; CRF: case report form; PI: principal investigator.

Declarations

Acknowledgements

We thank Institute of Chinese Medical History and Literature, China Academy of Chinese Medical Sciences for its supervision and support on protocol implementation and safety control of the trial. We are grateful to INTELLIGENCE FUTURE Soft Co., Ltd. For their statistical management. We also extend thanks to No. 1 Affiliated Hospital of Guizhou University of traditional Chinese Medicine, No. 2 Affiliated Hospital of Guizhou University of traditional Chinese Medicine for their kind assistance and collaboration.

Funding

The study is financially supported by National Key Research and Development Project of China (2019YFC1708403)

Availability of data and materials

Not applicable.

Authors' contributions

JC and JF designed the trial. XZW drafted the manuscript. KYX, PNC, and CHX will participate in data collection and statistical processing. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent to publish

Written informed consent was obtained from the participant for publication of her individual details and accompanying images in this manuscript. The consent form is held by the authors and is available for review by the Editor-in-Chief.

Ethics approval and consent to participate

The protocol (protocol version 2.0, 29 September, 2020) was approved by the ethic committee of No.1 Affiliated Hospital of Guizhou University of traditional Chinese Medicine(reference K2020-039). The study will be conducted in accordance with the principles of the Declaration of Helsinki. All study patients will sign the written informed on sent form prior to participation. Participation in the study is completely voluntary. Patients will be able to withdraw at any time. The decision to participate or withdraw will not affect their existing treatment or service received. Caregivers who are found to have significant depressive symptoms or other mental health problems will be referred to appropriate health services for follow-up. All personal information collected will be kept strictly confidential and used for research purposes only. Research team members will be responsible for safekeeping the confidential data. Only the PI and designated research staff will have access to the final trial dataset. The model consent form is provided in Additional file 2.

Dissemination

In addition to publishing articles, the database will also be published (Intelligence Future-TIANJIN Science&Technology Lte Co., Ltd. <http://www.ifscience.net>, IWR and EDC system).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China.

²The First Affiliated Hospital of Guizhou University of Traditional Chinese medicine-Guiyang 550001, China.

References

1. Zhou M W, Yue S W, He C Q, et al. Chinese Expert Consensus on Rehabilitation therapy for Lumbar Disc Herniation. *Chinese Journal of Rehabilitation Medicine*, 2017;32(02):129-135.
2. Cheng Z X, Zheng Y J, Feng Z Y, et al. Chinese Association for the Study of Pain: Expert consensus on diagnosis and treatment for lumbar disc herniation. *World J Clin Cases*, 2021;9(9):2058-2067.
3. Wang X S, Sun R F, Ji Q, et al. A meta-analysis of interlaminar minimally invasive discectomy compared to conventional microdiscectomy for lumbar disk herniation. *Clin Neurol Neurosurg*,

- 2014,127:149-157.
4. Graded Diagnosis and Treatment Guidelines for Lumbar Disc Herniation in Anhui Province (2015 Edition). *Anhui Medical Journal*, 2016,37(01):14-20.
  5. Lee J H, Choi T Y, Lee M S, et al. Acupuncture for acute low back pain: a systematic review. *Clin J Pain*, 2013,29(2):172-185.
  6. Liu L, Skinner M, McDonough S, et al. Acupuncture for low back pain: an overview of systematic reviews. *Evid Based Complement Alternat Med*, 2015:328196.
  7. Liang F F, Chen W Y, Chen B, et al. Effect of acupuncture therapy on patients with low back pain: a Meta-analysis. *Zhong guo Gu Shang*, 2016,29(5):449-455.
  8. Cho Y J, Song Y K, Cha Y Y, et al. Acupuncture for chronic low back pain: a multicenter, randomized, patient-assessor blind, sham-controlled clinical trial[J]. *Spine* (Phila Pa 1976), 2013,38:549-557.
  9. Molsberger A F, Mau J, Pawelec D B, et al. Does acupuncture improve the orthopedic management of chronic low back pain—a randomized, blinded, controlled trial with 3 months follow up. *Pain*, 2002,99(3):579-587.
  10. Qaseem A, Wilt T J, McLean R M, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med*, 2017,166(7):514-530.
  11. HU Y G. *lumbar disc herniation—fourth edition*. Bei Jing: People's Medical Publishing House, 2011:174
  12. WU M H, Wang X Y. *Chinese internal medicine —9th edition*. Bei Jing: China press of Traditional Chinese Medicine, 2012:389-390
  13. Kerr D P, Walsh D M, Baxter D. Acupuncture in the management of chronic low back pain: a blinded randomized controlled trial. *Clin J Pain*, 2003,19(6):364-370.
  14. *General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, Standardization Administration of the People's Republic of China. Nomenclature and location of acupuncture points*. Beijing: China Standards press; 2006.
  15. Standard of China Association of Acupuncture-Moxibustion. Evidence-Based Guidelines of Clinical Practice with Acupuncture and Moxibustion Low Back Pain. Beijing: *China press of Traditional Chinese Medicine*, 2014.
  16. *General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, Standardization Administration of the People's Republic of China. Standardized manipulations of acupuncture and moxibustion-Part 20: basic techniques of filiform needle*. Beijing: China Standards press; 2009.
  17. *General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, Standardization Administration of the People's Republic of China. Standardized manipulations of acupuncture and moxibustion-Part 21: filiform needle manipulation by basic applying technique*. Beijing: China Standards press; 2014.

18. Scott J, Huskisson E C. Graphic representation of pain. *Pain*, 1976,2(2):175-184.
19. Zai F L, Wu R L, Zheng M F, et al. Warming needle moxibustion relieves symptoms of lumbar disc herniation patients and upregulates plasma β -endorphin . *Acupuncture Research*, 2018,43(08):512-515.
20. Yang S, Yang X F, Jiang Y, et al. Effect of medicinal-cake-separated moxibustion on functional activity of back-leg and plasma substance P level in patients with lumbar disc herniation. *Acupuncture Research*, 2014,39(06):491-495.
21. Zheng G X, Zhao X O, Liu G L. Reliability of the modified Oswestry disability index for evaluating patients with low back pain. *Chinese Journal of Spine and Spinal Cord*, 2002(01):13-15.
22. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. *Spine (Phila Pa 1976)*, 1983,8(2):141-144.
23. Japanese O A. Japanese Orthopaedic Association. Assessment of surgical treatment of low back pain. *J Jpn OrthopAssoc*, 1984,58:1183-1187.
24. Wei W Z, Ruan Y D, Ning X J, et al. Clinical research on elongated needle combined with herb-partitioned moxibustion in the treatment of lumbar disc herniation. *Zhong guo Zhen Jiu*, 2013,33(8):673-677.
25. Pan M J, Qi X W, Wen T Y. Effect of cake-separated moxibustion combined with bloodletting therapy on plasma substance P, lumbar function and pain degree in patients with chronic low back pain. *Liaoning Journal of Traditional Chinese Medicine*, 2020,47(08):169-171.
26. Jin X C. Clinical effects of herbal-cake-separated moxibustion on lumbar disc herniation. Shan University of Traditional Chinese Medicine, 2019.
27. Tian F X, Li L Y, Jing X C. Analysis of the action modes and mechanism of partition moxibustion among acupoints, medicines, and moxibustion. *Journal of Shanxi University of Chinese Medicine*, 2018,19(06):39-41.

Tables

Due to technical limitations, table 1 is only available as a download in the Supplemental Files section.

Figures

Figure 1

Flow chart of the trial.

	STUDY PERIOD				
	Inclusion	Allocation	Post-allocation		Follow-up
TIMEPOINT	-Day2	0	Day7	Day14	Day28
ENROLMENT:					
Inclusion confirmed	X				
Informed consent	X				
Vital signs	X				
Medical history	X				
Treatment history	X				
Comorbidity	X				
Current treatment	X			X	
INTERVENTIONS:					
Ma's bamboo-based medicinal moxibustion					
Acupuncture					
ASSESSMENTS:					
VAS		X	X	X	X
ODI		X	X	X	X
M-JOA		X	X	X	X
β-EP		X		X	
SP		X		X	
Compliance analysis				X	X
Causes of dropout				X	X
Adverse event				X	X
Safety analysis				X	X

Figure 2

The SPIRIT figure. The schedule of enrollment, interventions and assessments. VAS, visual analogue scale; S-EP: β -endorphin; SP: Substance P; ODI: Oswestry disability index; M-JOA: Modified Japanese Orthopaedic Association low back pain Score.

Figure 3

Ma's bamboo-based medicinal moxibustion treatment

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table1a.jpg](#)
- [Table1b.jpg](#)

- [Additionalfile1SPIRIT2013Checklist.doc](#)